Last reviewed · How we verify
ImMucin, hGM-CSF
At a glance
| Generic name | ImMucin, hGM-CSF |
|---|---|
| Sponsor | Vaxil Therapeutics Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ImMucin, hGM-CSF CI brief — competitive landscape report
- ImMucin, hGM-CSF updates RSS · CI watch RSS
- Vaxil Therapeutics Ltd. portfolio CI